Insider buying last 90 days
No open-market insider purchases were filed for ZBH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week brings a wave of product and strategic news from Zimmer Biomet. The company raised its 2026 sales growth and adjusted earnings outlook after third-quarter strength in hips, surgical specialties and technology offset continued softness in knees. It also outlined manufacturing changes, consolidating production in Warsaw and shifting some distribution to Indianapolis by the end of 2028, with roughly $60 million in exit costs expected from facility consolidation in Indiana, New Jersey and Switzerland. Separately, Zimmer Biomet introduced "Surgeon-Guided Autonomy," a new technology framework linking surgical planning, execution and recovery, and announced it will present at the Jefferies Global Healthcare Conference in London on 19 November.
ZBH closed at $108.33, up 2.6%, sitting above both its 50-day average of $95.27 and 200-day average of $92.14, with the 50-day above the 200-day. The GekkoIndex reads 44.4, placing the stock in the Distribution zone, down 11.2 over five readings. Despite the supportive trend, price remains 37.1% below Gekko Fair Value of $172.24.
The next earnings date is 9 February 2027, 91 days out and beyond a typical 20-day holding window. Smart money activity shows one Congressional buy and no sales over the past 90 days, alongside one unusual options signal in the past 30 days, with put premium of $670,000 and no call premium noted. Seasonality from this point has averaged a 4% gain over 20 trading days across 5 years, rising in 3 of them. Analyst consensus stands at 16 firms with 3 buy and 13 hold ratings, and a consensus target of $106.90.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Zimmer Biomet scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Above 50 and 200-day
Close $103.21 is above the 50-day ($95.77) and 200-day ($92.53) averages, and the 50-day is above the 200-day.
See the chart53.5, Neutral
Reading 53.5 is in the Neutral zone.
See the GekkoIndex38.9% below
Price is 38.9% below Gekko Fair Value (more than 5% below).
See fair valueMixed
Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 1 unusual options signal.
See smart moneyReports in 86 days
Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.
See earnings+3.3% on average
From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Zimmer Biomet closed at $103.21 on Nov 13, 2026, +14.6% over the past year, inside a 52-week range of $79.12 to $112.55.
Use the left and right arrow keys to read daily values.
Put ZBH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Zimmer Biomet develops, produces, and sells devices used in orthopedic reconstruction, the kind of surgery that repairs or replaces joints. Alongside these core products, it makes items for sports medicine, biologics, extremities and trauma care, spine and craniomaxillofacial and thoracic treatment, dental implants, office-based technology, and other surgical tools, serving hospitals and medical practices that rely on these products in patient care.
The business is structured around three geographic segments. The Americas segment covers the United States along with other markets across North, Central, and South America. The Europe, Middle East and Africa segment includes countries such as France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment spans markets including Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia.
Zimmer Biomet traces its founding to Justin O. Zimmer in 1927 and keeps its headquarters in Warsaw, Indiana. Its shares are listed on the NYSE under the ticker ZBH.
Zimmer Biomet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 8.3 points over five sessions.
Up 8.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +1.2% | +1.1% | ||
| Accumulation | 296 | +0.5% | +1.3% | ||
| Neutral (current zone) | 347 | −0.7% | −2.0% | ||
| Distribution | 12 | −0.6% | −7.6% | ||
| Selling | 1 | Too few readings yet | |||
Average ZBH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Zimmer Biomet trades 38.9% below Gekko Fair Value of $168.83, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zimmer Biomet shares are worth, recalculated every trading day.
$168.83
Gekko Fair Value, Nov 14, 2026
38.9% Undervalued
At the end of Aug 2026 the price was 2.8% below the estimate.
No open-market insider purchases were filed for Zimmer Biomet, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ZBH in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 11 |
From congressional disclosures, which report amounts as ranges.
Zimmer Biomet has been buying back its own shares.
From company filings.
1signal, 0% of the flagged premium in calls.
Latest: Bearish flow on Oct 15, $670K in unusual premium.
1of the funds Gekko tracks holds ZBH.
Zimmer Biomet reports on Feb 9, 2027, before the open (86 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 9, 2027
Expected before the open, 86 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.07 est $2.01 | $2.18B est $2.13B | +1.4% |
| Apr 28, 2026 | $2.09 est $1.86 | $2.09B est $2.07B | −13.5% |
| Feb 10, 2026 | $2.42 est $2.40 | $2.24B est $2.22B | +6.6% |
| Nov 5, 2025 | $1.90 est $1.88 | $2.00B est $2.01B | −14.2% |
| Aug 7, 2025 | $2.07 est $1.98 | $2.08B est $2.06B | +8.9% |
| May 5, 2025 | $1.81 est $1.77 | $1.91B est $1.90B | −9.9% |
| Feb 6, 2025 | $2.31 est $2.29 | $2.02B est $2.01B | −6.8% |
| Oct 30, 2024 | $1.74 est $1.74 | $1.82B est $1.80B | +2.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Zimmer Biomet is $116.24, +12.6% from the last close, from 16 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 16 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Barclays | $115 | +11.4% |
| Nov 9 | Piper Sandler | $110 | +6.6% |
| Nov 5 | UBS | $130 | +26.0% |
| Nov 5 | Truist Financial | $114 | +10.5% |
| Nov 5 | J.P. Morgan | $120 | +16.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Zimmer Biomet averaged +3.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 3 of 5 |
| Next 10 trading days | +1.8% | 4 of 5 |
| Next 15 trading days | +3.0% | 3 of 5 |
| Next 20 trading days | +3.3% | 3 of 5 |
| Next 30 trading days | +3.9% | 3 of 5 |
For scale, ZBH’s typical 20-trading-day move in either direction is about 4.8%.
Zimmer Biomet’s market cap is $19.53B, with a P/E ratio of 26.1 and revenue of $8.57B over the last twelve months.
Coverage of Zimmer Biomet this week reads positive: 5 positive, 3 neutral and 0 negative headlines.
Zimmer Biomet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Zimmer Biomet’s market cap is $19.53B at the Nov 13, 2026 close of $103.21, with 189.3M shares outstanding. The shares trade on a P/E ratio of 26.1.
The consensus analyst 12-month price target for Zimmer Biomet is $116.24, +12.6% from the last close. Of the 16 firms that rated the stock in the last 90 days, 3 rate it a buy, 13 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Zimmer Biomet is undervalued: the Nov 13, 2026 close of $103.21 is 38.9% below Gekko Fair Value of $168.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Zimmer Biomet is expected to report on Feb 9, 2027, before the market opens (86 days away). Analysts expect earnings of $2.49 per share on revenue of $2.29B. Zimmer Biomet beat the earnings estimate in 7 of its last 8 reports, moving 8% on average across the report.
Zimmer Biomet’s 52-week high is $112.55 and its 52-week low is $79.12; it closed at $103.21 on Nov 13, 2026, +14.6% over the past year. Over the last five years the shares peaked at $149.25 on May 2, 2023.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, earnings risk and seasonality), 2 as mixed (gekkoindex and smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Zimmer Biomet over the last 30 days, with $0 of flagged premium in calls and $670K in puts. The latest, bearish flow, was on Oct 15, 2026 with $670K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.